AngioInsight

AngioInsight is a private, pre-revenue biotech company pioneering AI-powered diagnostic software for cardiovascular disease. Its core investigational platform, AngioAI+™, analyzes routine angiograms to provide combined assessments for epicardial blockages (CAD) and microvascular dysfunction (CMD), addressing a significant unmet need in cardiology, particularly for patients with ischemia but no obstructive coronary arteries (INOCA). The company is led by a seasoned team with expertise in AI/ML, cardiovascular medicine, and medical device regulation, positioning it to tackle the diagnostic challenges and subjective visual assessments that currently dominate angiography.

AI/ML software (AngioAI+™) that analyzes standard angiographic video to provide assessments for stenosis, physiology, and microvascular function without additional hardware.

AngioInsight competes in the crowded cardiovascular AI diagnostics market, which includes companies offering AI for quantitative coronary angiography (QCA), CT-based FFR (e.g., HeartFlow), and intravascular imaging analysis. Its primary differentiation is the combined assessment of epicardial and microvascular disease from a standard angiogram, a niche with fewer direct competitors.